CTMX — CytomX Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Mar 18, 2026 • 02:46 UTC GlobeNewswire Inc. • Cytomx Therapeutics, Inc.

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.

CTMX AMGN BMY CELGR capital raise public offering Varseta-M ADC

Sentiment note

The company successfully priced a substantial $250 million capital raise, demonstrating investor confidence and providing significant funding to advance clinical development of Varseta-M and pipeline programs. This capital infusion supports the company's ability to execute on its oncology-focused strategy.

Neutral Feb 4, 2026 • 13:00 UTC GlobeNewswire Inc. • Not Specified

CytomX Therapeutics to Present at Upcoming February Conferences

CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to advance its pipeline including varsetatug masetecan and CX-801.

CTMX AMGN BMY CELGR CytomX Therapeutics masked biologics PROBODY platform varsetatug masetecan

Sentiment note

The announcement is routine corporate disclosure regarding conference participation. While it demonstrates continued investor engagement and pipeline advancement, there is no material clinical data, financial results, or strategic developments that would warrant positive or negative sentiment. The tone is informational rather than indicative of significant company progress or setbacks.

Positive Nov 13, 2025 • 13:00 UTC GlobeNewswire Inc. • Cytomx Therapeutics

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.

CTMX AMGN ALPMY BMY oncology biologics cancer treatment clinical trials

Sentiment note

Company is progressing clinical trials, presenting new data, and has strategic collaborations with major pharmaceutical companies

Neutral Oct 30, 2025 • 12:00 UTC GlobeNewswire Inc. • Cytomx Therapeutics

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.

CTMX AMGN ALPMY BMY financial results conference call webcast oncology

Sentiment note

Standard financial reporting announcement with no explicit positive or negative indicators

Positive Sep 25, 2025 • 21:06 UTC Benzinga • Benzinga Staff Writer

12 Health Care Stocks Moving In Thursday's After-Market Session

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

CTMX GLTO DRIO ORGO healthcare stocks after-market trading

Sentiment note

Stock increased by 9.14% to $3.1, with a market value of $397.4 million

Neutral Aug 7, 2025 • 22:29 UTC The Motley Fool • Na

CytomX (CTMX) Q2 Revenue Drops 26%

CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.

CTMX BMY CELGR AMGN biotechnology oncology clinical trials revenue decline

Sentiment note

Mixed financial performance with revenue decline (-25.6%) offset by cost controls, positive clinical pipeline developments, and a $100 million capital raise ensuring cash runway through Q2 2027

Neutral Jul 9, 2025 • 12:30 UTC Benzinga • Prnewswire

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

CLDI VRTX IBRX CRSP cancer genetic medicine virotherapy oncology

Sentiment note

Updated pipeline priorities focusing on developing CX-2051 for metastatic colorectal cancer

Positive Apr 28, 2025 • 20:00 UTC GlobeNewswire Inc. • Cytomx Therapeutics

CytomX Therapeutics Presents Preclinical Data for mRNA Encoded Masked IL-12 Molecule in Collaboration with Moderna at AACR Annual Meeting

CytomX Therapeutics and Moderna presented preclinical data on an mRNA-encoded masked IL-12 molecule, which showed potent anti-tumor activity with enhanced tolerability.

CTMX MRNA CytomX Therapeutics Moderna mRNA IL-12 cancer preclinical

Sentiment note

The article highlights the positive preclinical data for CytomX's mRNA-encoded masked IL-12 molecule, which demonstrated improved anti-tumor efficacy and tolerability.

Positive Mar 5, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

CytomX Therapeutics to Present at the Barclays 27th Annual Global Healthcare Conference

CytomX Therapeutics, a biopharmaceutical company focused on developing novel conditionally activated biologics for cancer treatment, announced that its CEO will present at the Barclays Global Healthcare Conference. The company's pipeline includes several clinical-stage candidates targeting various cancer types.

CTMX CytomX Therapeutics cancer treatment biologics Barclays Global Healthcare Conference

Sentiment note

The article highlights CytomX's progress in developing a pipeline of novel cancer treatments, which suggests the company is making advancements in its field.

Unknown Jun 17, 2024 • 20:15 UTC GlobeNewswire Inc. • CytomX Therapeutics Inc.

CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the promotion of Chris Ogden to Chief Financial Officer effective June 15, 2024.

CTMX Directors and Officers Health

Unknown May 22, 2024 • 20:05 UTC GlobeNewswire Inc. • CytomX Therapeutics Inc.

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 8:30 a.m. ET.

CTMX Calendar of Events

Unknown May 16, 2024 • 20:15 UTC GlobeNewswire Inc. • CytomX Therapeutics Inc.

CytomX Therapeutics Announces New Employment Inducement Grants

SOUTH SAN FRANCISCO, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that on May 15, 2024, the Company granted two new employees options to purchase a total of 130,000 shares of the Company’s common stock at an exercise price per share equal to $1.96, which was the closing price on May 15, 2024, the date of the grants.

CTMX Health Major shareholder announcements